Roswell Park Comprehensive Cancer Center has formed an academic cooperation with the Jagiellonian University in Kraków.
The collaboration will see the two centers exchanging staff, students and scientific resources to undertake basic, translational and clinical research in order to advance the development of cancer therapies.
The agreement grew out of a July 2018 visit by Polish Secretary of State Anna Maria Anders to Roswell Park. Four Roswell Park faculty leaders, joined by Anders, recently traveled to Kraków to initiate the collaboration: Kunle Odunsi, deputy director, chair of gynecologic oncology and executive director of the Center for Immunotherapy; Pawel Kalinski, vice chair for translational research and Rustum Family Professor for Molecular Therapeutics and Translational Research; Agnieszka Witkiewicz, director of the Center for Personalized Medicine and chief for research in the Department of Pathology; and Danuta Kozbor, associate professor of immunology and microbiology.
The agreement is effective immediately, and could see exchange of students and faculty between the two centers as early as spring 2019.
Roswell Park partners with Jagiellonian University in Kraków
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
THE CLINICAL CANCER LETTER
YOU MAY BE INTERESTED IN
Nov. 6, 2023, was a bad day for Tom Curran, a charming scientist with a lilting Scottish brogue and the lifelong dream of curing childhood cancers.


Credit: OHSU/Christine Torres HicksAfter a year as director of the Oregon Health and Science University’s Knight Cancer Institute, Tom Sellers has stepped down from his position. He is replaced by Lisa Coussens, chair of the Department of Cell, Developmental & Cancer Biology, who was appointed interim center director.


In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.


Thomas B. Tomasi Jr., who led Roswell Park Comprehensive Cancer Center as president and CEO from 1986 to 1996, died March 23 at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s top cancer centers.


Dr. Thomas B. Tomasi, Jr. president and CEO of Roswell Park Comprehensive Cancer Center from 1986 to 1996, died on March 23. He was 97.

